Affimed(AFMD) Newsfilter·2024-12-17 11:30Core Insights - The combination of AFM24 and atezolizumab shows promising clinical activity in heavily pretreated NSCLC patients, with an overall response rate (ORR) of 21% in EGFR wild-type patients and 24% in EGFR mutant patients, alongside a disease control rate (DCR) of 76% and 71% respectively [1][7][10] - A post-hoc analysis indicates that higher exposure to AFM24 correlates with significantly improved response rates and progression-free survival (PFS), leading to a planned increase in dosage to 720 mg weekly for future development [1][9][10] NSCLC EGFR Wild-type Cohort Update - The patient population included 43 patients in the full analysis set, with 33 in the per protocol set, having a median of 2 prior lines of therapy [3] - The combination therapy resulted in an ORR of 21%, with tumor shrinkage observed in 48% of patients and a preliminary median PFS of 5.6 months [5] NSCLC EGFR Mutant Cohort Update - The cohort consisted of 28 patients in the full analysis set, with 17 patients in the per protocol set, all having received prior EGFR-specific TKI therapy [6] - The combination therapy achieved an ORR of 24%, with tumor shrinkage in 41% of patients and a median PFS of 5.6 months [7] Safety Profile - The combination therapy was well tolerated, with infusion-related reactions being the most common adverse event reported in 54% of patients, and no unexpected safety findings were identified [4][10] Post-Hoc Exposure-Response Analysis - The analysis included 44 patients treated with 480 mg AFM24, revealing that the high exposure group had an ORR of 46% and a median PFS of 7.4 months, indicating a clear relationship between exposure and efficacy [8][9] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer, with its proprietary ROCK® platform generating innovative innate cell engagers (ICE®) for targeted tumor therapy [11][12]